IMMUNOTROPIC AGENTS IN COMPLEX TREATMENT OF CHILDREN WITH INTERMITTENT ALLERGIC RHINITIS AND RECURRENT RESPIRATORY INFECTIONS

Abstract

The purpose of the research was to develop a prescribing of immunomodulators Imudon, Viferon, Superlymph in the complex treatment of frequently ill children (FIC) with a frequency of ARI 6 or more times a year, foci of chronic infection in oro and nasopharynx, and intermittent (seasonal) AR mild or moderate severity (SAR). Methods: 120 FIC from 5 to 7 years old (56 boys and 64 girls) were followedup during 2 years. Investigation revealed pollen and household allergens predomination in the spectrum of causesignificant allergens. Microbial landscape of chronic infection foci in the oro and nasopharynx was characterized by a predominance of Staphylococcus aureus in 71,2%, Candida albicans in 28,8%, Streptococcus haemolyticus in 50% of patients. In 67.4% of patients microbial associations of 2 and 3 pathogens predominated. Immune system abnormalities were characterized by reduction in T cells, the level of serum IgA in 62.5%, gammaIFN – in 80%, alphainterferon – a 60% increase in serum IgG – at 62,5%, TNFα – 80,0%, and IgE – in 100% of the children. Supplementation of Imudon, Superlymph and Viferon as a component of complex treatment of this category of children reduces the mucous contamination with active forms of Candida albicans by 24 times, with bacterial flora ( Staphylococcus aureus, Streptococcus spp. ) in 2 3,4 times, reduces inflammation of the mucous membranes of oro and nasopharynx, adenoid hypertrophy, reduces the frequency of ARI in 1,9, 2,5 and 3,1 times respectively. In 16,6% of FIC with SAR who did not receive immunomodulators in complex treatment, persistent AR developed in a year of observation. Cases of persistent AR in groups of children receiving Superlymph or Viferon were not revealed.

Keywords

frequently ill children / immunological parameters / AR intermittent mild and moderate severity (SAR) / immune drugs (Viferon / Imudon / Superlymph)

References

[1] Коровина Н.А., Заплатников А.Л., Чебуркин А.В., Захарова И.Н. Часто и длительно болеющие дети: современные возможности иммунореабилитации: Руководство для врачей. М.: Контимед, 2001. 68 с.

[2] Маркова Т.П., Чувиров Д.Г. Применение топических иммуномодуляторов в группе длительно и часто болеющих детей / В кн. Иммунокоррекция в педиатрии под ред. М.В. Костинова. М.,2001. С.91-99.

[3] Пискунов С.З., Пискунов Г.З. Клиническая ринология. М.: Миклош, 2002.

[4] Ильина Н.И. Аллергический ринит // Consilium Medicum. 2000. Т. 1, № 8. С. 338-344.

[5] Schröder N.W., Crother T.R., Naiki Y. et al. Innate immune responses during respiratory tract infection with a bacterial pathogen induce allergic airway sensitization // J. Allergy Clin. Immunol. 2008. Vol. 122 (3). Р. 595-602.

[6] Аллахвердиева Л.И. Некоторые аспекты патогенеза и лечения респираторной аллергопатологии у детей и подростков // Иммунология. 2006. № 1. С. 34-40.

[7] Martinez F.D. Development of wheezing disorders and asthma in preschool children // Pediatrics. 2002. Vol. 109. Р. 362-367.

[8] Zakrzewska A., Kobos J., G\rski P. The implications of nasal associated lymphoid tissue in development of respiratory allergic diseases in children // Med. Wieku Rozwoj. 2007. Vol. 11 (2 Pt 1). Р. 129-134.

[9] Holgate S.T., Broide D. New targets for allergic rhinitis – a disease of civilization // Nat. Rev. Drug Discov. 2003. 2 (11). P. 902-914.

[10] Гущина Я.С., Касснер Л.Н., Маркелова Е.В., Ицкович А.И. Уровень провоспалительных цитокинов в оценке активности воспалительного процесса при бронхолегочной патологии у детей // Цитокины и воспаление. 2006. Т. 5, № 4. С. 36-38.

[11] Маркова Т.П. Иммунотропные препараты в педиатрии // Доктор РУ. 2008. № 1. С.48-52.

RIGHTS & PERMISSIONS

Chigaeva E.V., Grankina N.E.